Opus Genetics raises $25M via Series B convertible preferred; pro forma cash $70M

Opus Genetics, Inc.

Closed private placement of 7,374,632 shares of Series B Non-Voting Convertible Preferred at $3.39/share for $25M.
Proceeds to advance gene therapy clinical programs, working capital, and general corporate purposes.
Preliminary cash balance $45M as of Dec 31, 2025; pro forma $70M after private placement proceeds.
Conversion to common stock requires stockholder approval at 2026 annual meeting; filing of Certificate of Designation.
Company entered into Registration Rights Agreement to register resale of conversion shares by April 19, 2026.

item 1.01 item 2.02 item 3.02 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Opus Genetics, Inc. entered into Registration Rights Agreement with the Purchasers valued at Company will register the resale of shares of Common Stock issuable upon conversion of Series B Pref (effective 2026-02-18).

Action: entry
Agreement: equity purchase
Counterparty: the Purchasers
Value: Company will register the resale of shares of Common Stock issuable upon conversion of Series B Pref
Effective: 2026-02-18

Exact text from the filing

In connection with the Private Placement, the Company also entered into a Registration Rights Agreement, dated February 18, 2026 (the “Registration Rights Agreement”), with the Purchasers, which provides that the Company will register the resale of the shares of Common Stock issuable upon conversion of the Series B Preferred Stock.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Opus Genetics, Inc. entered into Securities Purchase Agreement with certain purchasers valued at Aggregate purchase price of approximately $25.0 million for 7,374,632 shares of Series B Non-Voting (effective 2026-02-13).

Action: entry
Agreement: equity purchase
Counterparty: certain purchasers
Value: Aggregate purchase price of approximately $25.0 million for 7,374,632 shares of Series B Non-Voting
Effective: 2026-02-13

Exact text from the filing

On February 13, 2026, Opus Genetics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain purchasers (the “Purchasers”) for a private placement (the “Private Placement”) of an aggregate of 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”).

View on SEC.gov

300 material agreements filed in the last 30 days. Browse all material agreements →

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-26-006176

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.